FDA guidance
Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4 Guidance for…
FDA guidance · Final · issued Mar 22, 2022
Key facts
| Title | Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4 Guidance for Industry: Guidance for Industry |
|---|---|
| Status | Final |
| Issue date | Mar 22, 2022 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, Center for Drug Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Biologics, Drugs, Medical Devices |
| Docket number | FDA-2022-D-0192 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents